Tucscon, Ariz.-based Ventana, a subsidiary of Roche, earned Food and Drug Administration approval for the Ventana PD-L1 Assay.
The assay functions as a diagnostic tool to identify PD-L1 levels in patients considering treatment with Roche's cancer drug Tecentriq. PD-L1 is a protein that makes individuals more receptive to immunotherapy treatments.
Better insight into a patient's PD-L1 levels can indicate the potential survival benefits associated with using Tecentriq as a treatment.
More articles on supply chain:
EpiPen price hikes cost DOD millions
Kits for care: How global sourcing helped Northside Hospital boost patient comfort
FDA approves Medtronic's larger aortic valve replacement system